|
Apr 3
|
Protagonist Therapeutics Inc CEO Sells 25,000 Shares
|
|
Apr 1
|
Shareholders have faith in loss-making Protagonist Therapeutics (NASDAQ:PTGX) as stock climbs 3.7% in past week, taking five-year gain to 135%
|
|
Mar 26
|
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
|
|
Mar 18
|
Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet
|
|
Mar 18
|
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda
|
|
Mar 11
|
Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year
|
|
Mar 6
|
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
|
|
Mar 5
|
Zacks.com featured highlights Protagonist Therapeutics, AxoGen, Western Digital and Phunware
|
|
Feb 7
|
New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study
|
|
Jan 12
|
Insider Suneel Gupta Sells 5,000 Shares of Protagonist Therapeutics Inc (PTGX)
|
|
Dec 31
|
A Look At The Fair Value Of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
|
|
Nov 27
|
Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib
|
|
Sep 5
|
Protagonist Therapeutics to Present at Upcoming Investor Conferences
|
|
Aug 9
|
Protagonist Receives $34 Million from Warrant Exercises
|
|
Jul 5
|
Protagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival Treatment
|
|
Jul 4
|
Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis
|
|
Jun 30
|
Protagonist Therapeutics (PTGX) Is a Great Choice for 'Trend' Investors, Here's Why
|